Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$27,000.00

Protease Engineering to Enhance Alphavirus Vector Efficiency: Advancing Vaccine and Therapeutic Strategies

FY 2024-25

Summary
The COVID-19 pandemic has highlighted the need for innovative vaccines and treatments that go beyond traditional methods. One promising approach is self-amplifying RNA (saRNA) vaccines, which use a specialized RNA platform to produce a stronger immune response with smaller doses. For example, the ARCT-154 vaccine, recently approved in Japan, is based on this technology. Unlike standard mRNA vaccines, saRNA includes instructions that help it replicate itself once inside the body, reducing the need for large doses and potentially leading to longer-lasting immunity. This platform uses a modified alphavirus system containing key proteins (called nsPs 1-4) and a viral promoter to enhance RNA production. It also being studied for applications beyond vaccines, such as cancer therapies and targeted delivery of genetic material to specific cells. However, the efficiency of saRNA systems relies heavily on the activity of one protein in particular;nsP2, an alphavirus protease. This protein acts like molecular scissors, processing other proteins to enable RNA amplification. Improving the activity of nsP2 could make saRNA vaccines and therapies more effective. This project aims to enhance nsP2 activity by introducing controlled changes to its structure (structure-based mutagenesis) and generating random variations (random mutagenesis). A library of modified nsP2 proteins will be tested using a fluorescence-based method to identify those with the best activity. By creating more efficient nsP2 variants, this research aims to improve RNA production, reduce side effects, and make vaccines and therapies more accessible. This work could address the limitations of current mRNA technologies and expand the potential of saRNA for a range of medical applications.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530004
Name
Demmon Sydney M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Protease Engineering to Enhance Alphavirus Vector Efficiency: Advancing Vaccine and Therapeutic Strategies
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Activity; Alphaviruses; Crystallization; Enzymes; Mrna; Mutagenesis; Proteases; Sarna; Therapeutics; Vaccines
Abstract
The COVID-19 pandemic has highlighted the need for innovative vaccines and treatments that go beyond traditional methods. One promising approach is self-amplifying RNA (saRNA) vaccines, which use a specialized RNA platform to produce a stronger immune response with smaller doses. For example, the ARCT-154 vaccine, recently approved in Japan, is based on this technology. Unlike standard mRNA vaccines, saRNA includes instructions that help it replicate itself once inside the body, reducing the need for large doses and potentially leading to longer-lasting immunity. This platform uses a modified alphavirus system containing key proteins (called nsPs 1-4) and a viral promoter to enhance RNA production. It also being studied for applications beyond vaccines, such as cancer therapies and targeted delivery of genetic material to specific cells. However, the efficiency of saRNA systems relies heavily on the activity of one protein in particular;nsP2, an alphavirus protease. This protein acts like molecular scissors, processing other proteins to enable RNA amplification. Improving the activity of nsP2 could make saRNA vaccines and therapies more effective. This project aims to enhance nsP2 activity by introducing controlled changes to its structure (structure-based mutagenesis) and generating random variations (random mutagenesis). A library of modified nsP2 proteins will be tested using a fluorescence-based method to identify those with the best activity. By creating more efficient nsP2 variants, this research aims to improve RNA production, reduce side effects, and make vaccines and therapies more accessible. This work could address the limitations of current mRNA technologies and expand the potential of saRNA for a range of medical applications.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Demmon, Sydney M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~